News

News

June 8, 2023

Azafaros Announces Enrollment of First Patient in Phase 2 RAINBOW Study Evaluating AZ-3102 in GM2 and NP-C Patients

March 20, 2023

Azafaros Appoints Chief Operating Officer and Head of Finance

February 27, 2023

Beyond Biotech podcast 35: Rare Disease Day

February 20, 2023

Azafaros Receives Additional Regulatory Designations for AZ-3102 from FDA, EMA and MHRA

January 9, 2023

Azafaros Strengthens Medical and Scientific Management Team Reflecting Clinical Progress

January 5, 2023

BREAKING NEWS: Azafaros Receives FDA’s IND Clearance and Fast Track Designation

April 24, 2022

Azafaros Announces FDA Grant of Orphan Drug Designation for AZ-3102 in the Treatment of Niemann-Pick Disease

February 14, 2022

Azafaros Presents Positive Clinical and Preclinical Data Supporting Development of Lead Compound AZ-3102 in Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Conference

February 1, 2022

Azafaros Receives FDA Orphan Drug Designation for AZ-3102 in GM2 Gangliosidosis

January 18, 2022

Azafaros Announces Multiple Presentations at 18th Annual WORLDSymposium™

June 30, 2021

Azafaros Appoints Stefano Portolano, M.D., as Chief Executive Officer

April 6, 2021

Azafaros enters clinical stage with AZ-3102, an oral small molecule being developed for rare neurogenetic disorderss

June 10, 2020

Azafaros expands executive management team and operations

February 6, 2020

Azafaros completes EUR 25 million Series A financing to advance rare metabolic disorders pipeline

July 23, 2018

Azafaros B.V. secures seed funding to develop new treatments in rare metabolic disorders